P1.16-04. Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors
Back to course
Pdf Summary
Asset Subtitle
Niels Reinmuth, Germany
Meta Tag
Speaker Niels Reinmuth, Germany
Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
IASLC 2022 World Conference on Lung Cancer
EVOKE-01 phase 3 study
sacituzumab govitecan
non-small cell lung cancer (NSCLC)
platinum-based chemotherapy
checkpoint inhibitors
metastatic NSCLC
immune checkpoint inhibitors
antibody-drug conjugate
Powered By